Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus

Abstract

Nateglinide significantly increases insulin secretion in Type 2 diabetic patients, in particular restoring the first phase insulin response. Further study is necessary to determine the effects of chronic administration on insulin secretion and blood glucose concentration.